A Dark Vector Cognition product

Viatris 8-K 2026-11-17

VTRS · CIK 1792044 · Form 8-K · Period ended November 17, 2026 · Filed November 17, 2026

1 sections, 9K characters. Original on sec.gov · ·

The 12 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2026

VIATRIS INC.

(Exact name of registrant as specified in its charter)

Delaware001-3969583-4364296
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317

(Address of Principal Executive Offices)

(724) 514-1800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareVTRSThe NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.01Completion of Acquisition or Disposition of Assets.

As previously disclosed, on October 8, 2026, Viatris Inc., a Delaware corporation (“Viatris”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pacira BioSciences, Inc., a Delaware corporation (“Pacira”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned subsidiary of Viatris (“Purchaser”).

Pursuant to the Merger Agreement, on October 30, 2026, Purchaser commenced a tender offer (the “Offer”) to purchase all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Pacira for $36.50 per Share, in cash, net of applicable withholding taxes and without interest (the “Offer Price”), upon the terms and subject to the conditions set forth in the Merger Agreement.

On November 17, 2026, Viatris announced that the Offer and related withdrawal rights expired as scheduled at one minute after 11:59 p.m., Eastern Time, on November 16, 2026 (the “Expiration Time”) and that immediately prior to the Expiration Time, based on the information provided by the depositary agent for the Offer, a total of 32,929,780 Shares were validly tendered (and not validly withdrawn) pursuant to the Offer, representing approximately 66.46% of the Shares outstanding immediately prior to the Expiration Time. Accordingly, the number of Shares validly tendered (and not validly withdrawn) pursuant to the Offer (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received,” as such term is defined in Section 251(h)(6)(f) of the General Corporation Law of the State of Delaware (the “DGCL”), by the “depository,” as such term is defined in Section 251(h)(6)(c) of the DGCL), together with any Shares then owned by Purchaser and its affiliates, satisfied the Minimum Condition (as defined in the Merger Agreement), and all other conditions to the consummation of the Offer having been satisfied or waived, on November 17, 2026, Purchaser irrevocably accepted for payment all Shares that were validly tendered (and not validly withdrawn) pursuant to the Offer, and payment for such Shares will be made promptly in accordance with the terms of the Offer and the Merger Agreement.

Following the completion of the Offer, the remaining conditions to the Merger (as defined below) set forth in the Merger Agreement were satisfied or waived, and on November 17, 2026, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Pacira, without a vote of the stockholders of Pacira in accordance with Section 251(h) of the DGCL, with Pacira continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Viatris (the “Merger,” and the date and time at which the Merger became effective is referred to as the “Effective Time”). Pursuant to the Merger Agreement, at the Effective Time, each Share issued and outstanding immediately prior to the Effective Time (other than Shares that were held (i) by Pacira or any of its subsidiaries (including in Pacira’s treasury), (ii) by Viatris, Purchaser or any other wholly owned direct or indirect subsidiary of Viatris, which Shares were canceled and ceased to exist, and no consideration was delivered in exchange therefor, or (iii) by Pacira’s stockholders who were entitled to demand appraisal rights under, and properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in, Section 262 of the DGCL and, as of the Effective Time, had neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL) was converted into the right to receive the Offer Price, upon the terms and conditions set forth in the Merger Agreement.

The aggregate amount to be paid by Purchaser in the Offer and the Merger is approximately $1.69 billion, excluding related fees and expenses. Viatris and Purchaser will fund the acquisition of the Shares in the Offer and the Merger through a combination of cash on hand and short-term borrowings.

The foregoing description of the Merger Agreement and the related transactions does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by Viatris on October 8, 2026 and is incorporated herein by reference.

Item 7.01Regulation FD Disclosure.

On November 17, 2026, Viatris issued a press release announcing, among other things, the consummation of the Merger. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 7.01 and in Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description
2.1*Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc., Viatris Inc. and Peach Purchaser Sub Inc., incorporated herein by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by Viatris Inc. on October 8, 2026
99.1Press Release, dated November 17, 2026, issued by Viatris Inc.
104Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document
  • Schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Viatris hereby agrees to supplementally furnish to the SEC upon request any omitted schedule, exhibit or similar attachment to Exhibit 2.1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIATRIS INC.
Date: November 17, 2026By:/s/ Matthew J. Maletta
Matthew J. Maletta
Chief Legal Officer